MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee Boong Lee, Man Seong Park, Yong Sung Kim, Hosun Park, Dong Sik Kim

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.

Original languageEnglish
Article number778829
JournalFrontiers in immunology
Volume12
DOIs
Publication statusPublished - 2021 Nov 18

Keywords

  • MG1141A
  • SARS-CoV-2
  • monoclonal antibody
  • outbreak
  • spike protein

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants'. Together they form a unique fingerprint.

Cite this